# Telotristat With Lutathera in Neuroendocrine Tumors

Source: https://onco.cc/trials/nct04543955/  
OnCo record `nct04543955` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Telotristat ethyl in Neuroendocrine tumours, run by Lowell Anthony, MD, recorded as terminated on the registry.

## Summary

Telotristat With Lutathera in Neuroendocrine Tumors is a phase 2 interventional study registered as NCT04543955 by Lowell Anthony, MD, with 1 participants recorded, started 2021-09-13 and due to reach its primary completion in 2022-06-03. Interventions recorded: Telotristat (Low-Dose), Telotristat (High-Dose). Conditions recorded: Neuroendocrine Tumors.

Linked to the drug Telotristat ethyl because the registry names it among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04543955
- Phase: 2
- Setting: Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors
- Sponsor: Lowell Anthony, MD
- Enrolled: 1

## Sources

- ClinicalTrials.gov NCT04543955: https://clinicaltrials.gov/study/NCT04543955

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- drugs: [Telotristat ethyl](https://onco.cc/drugs/telotristat-ethyl/)

---
JSON: https://onco.cc/api/v1/entities/nct04543955.json